Abstract | OBJECTIVES: MATERIALS AND METHODS: Thirty-eight patients treated with SBRT and chemotherapy for locally advanced, borderline resectable, and medically inoperable pancreatic cancer at our institution from January 2008 to December 2012 were included in this retrospective analysis. Treatment was delivered in 5 fractions of 5 or 6 Gy per fraction over 5 days. Toxicities were scored using the Common Terminology Criteria for Adverse Events version 3. Survival was calculated using the Kaplan-Meier method. RESULTS: The median age was 70 years (range, 45 to 90 y). Eastern Cooperative Oncology Group performance status ranged from 0 to 3. Thirty-four patients received concurrent chemotherapy. Four patients received sequential chemotherapy. Median overall survival was 14.3 months and median progression-free survival was 9.2 months from diagnosis. From radiation, overall survival and progression-free survival were 12.3 and 6.8 months, respectively. The overall local control rate was 79%. Acute toxicity was minimal. Severe late SBRT-related toxicities included 1 grade 3 gastric outlet obstruction, 1 grade 4 biliary stricture, and 1 grade 5 gastric hemorrhage. CONCLUSIONS:
|
Authors | Marie K Gurka, Christine Kim, Aiwu Ruth He, Aline Charabaty, Nadim Haddad, Jenna Turocy, Lynt Johnson, Patrick Jackson, Louis M Weiner, John L Marshall, Sean P Collins, Michael J Pishvaian, Keith Unger |
Journal | American journal of clinical oncology
(Am J Clin Oncol)
Vol. 40
Issue 2
Pg. 152-157
(Apr 2017)
ISSN: 1537-453X [Electronic] United States |
PMID | 25171298
(Publication Type: Journal Article)
|
Topics |
- Adenocarcinoma
(therapy)
- Aged
- Aged, 80 and over
- Chemoradiotherapy
- Female
- Humans
- Male
- Middle Aged
- Pancreatic Neoplasms
(therapy)
- Radiosurgery
- Retrospective Studies
|